Trade CureVac N.V. - CVAC CFD

CureVac N.V. Company profile

CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).

The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’

CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.

The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.

CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.

According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.

According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.

You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.